PlainRecalls
FDA Drug Moderate Class II Ongoing

Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-60.

Reported: April 5, 2023 Initiated: March 14, 2023 #D-0533-2023

Product Description

Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-60.

Reason for Recall

CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.

Details

Recalling Firm
Ascend Laboratories, LLC
Units Affected
13,560 bottles
Distribution
Nationwide in the USA.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Dabigatran Etexilate Capsules, 75 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-474-60.. Recalled by Ascend Laboratories, LLC. Units affected: 13,560 bottles.
Why was this product recalled?
CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 5, 2023. Severity: Moderate. Recall number: D-0533-2023.